AVEO - AVEO Pharmaceuticals, Inc.
| Previous Close | 0.8181 |
| Open | 0.8300 |
| Bid | 0.8400 x 800 |
| Ask | 0.8469 x 1000 |
| Day's Range | 0.8255 - 0.8499 |
| 52 Week Range | 0.4900 - 2.8500 |
| Volume | 289,071 |
| Avg. Volume | 2,521,338 |
| Market Cap | 136.504M |
| Beta (3Y Monthly) | 0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1010 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.94 |
- Zacks
AVEO (AVEO) Upgraded to Strong Buy: What Does It Mean for the Stock?
AVEO (AVEO) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Business Wire
AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma
AVEO Oncology (AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with IMFINZI® (durvalumab), AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in patients with hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The Phase 1b portion will evaluate the safety, tolerability, dose limiting toxicity, maximum tolerated dose and preliminary anti-tumor activity starting with 1.0mg of tivozanib for 21 days followed by 7 days rest together with 1500mg of durvalumab every 28 days. Assuming satisfactory completion of the Phase 1b portion of the study, a Phase 2 expansion cohort will enroll at the dose schedule designated in Phase 1b.
- Business Wire
AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at 10:05 a.m. Eastern Time. AVEO Pharmaceuticals is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company’s lead candidate is tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, which AVEO is working to develop and commercialize in North America as a treatment for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and other cancers.
- Business Wire
AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
AVEO Oncology (AVEO) and EUSA Pharma today announced the upcoming presentation of final results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA®), AVEO’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in combination with intravenous (IV) nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced or metastatic renal cell carcinoma (RCC). The results will be presented at the European Society of Medical Oncology (ESMO) 2019 Annual Congress, in a poster presentation titled “TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC).
- Zacks
Renal Cell Carcinoma Space in Focus: Some Key Developments
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
- Zacks
AVEO (AVEO) Upgraded to Buy: What Does It Mean for the Stock?
AVEO (AVEO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
AVEO Surges on Favorable Updated OS Results on RCC Drug
AVEO posts positive updated results from the second prespecified overall survival analysis of Fotivda for treating highly refractory metastatic renal cell carcinoma. Stock up more than 30%.
- Zacks
Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus
Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.
- Business Wire
AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®) to sorafenib in 350 subjects with highly refractory metastatic renal cell carcinoma (RCC). Median OS, a point in time value separating the earlier half of events from the latter half within each arm, was 16.4 months for tivozanib (95% CI: 13.4-22.2) and 19.7 months for sorafenib (95% CI: 15.0-24.2).
- Zacks
AVEO (AVEO) Up 0.2% Since Last Earnings Report: Can It Continue?
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
- Zacks
AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag
AVEO Pharmaceuticals' (AVEO) loss is narrower than expected in the second quarter of 2019. However, revenues fall short of estimates.
- Zacks
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of 66.67% and -60.39%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
AVEO Pharmaceuticals (AVEO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
AVEO Pharmaceuticals Down More Than 50% YTD: Here's Why
AVEO Pharmaceuticals (AVEO) suffers a major setback as it delays the NDA filing for Fotivda in the United States.
- Zacks
AVEO (AVEO) Down 19.9% Since Last Earnings Report: Can It Rebound?
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
AVEO Oncology to Present at the 2019 BIO International Convention
AVEO Oncology (AVEO) today announced that Mike Ferraresso, Senior Vice President, Business Analytics and Commercial Operations, will present at the 2019 BIO International Convention in Philadelphia on Wednesday, June 5, 2019 at 4:30 p.m. EDT. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs.
- Business Wire
AVEO Oncology Announces Presentations at the 2019 ASCO Annual Meeting
AVEO Oncology today announced two poster presentations at the upcoming American Society of Clinical Oncology Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois.
- Zacks
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
- Zacks
AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Tops Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of -20.00% and 117.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
AVEO: 1Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had net income of 6 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
